Elisabeth Bjork Increases Stake in Rocket Pharmaceuticals Inc with New Share Purchase

Elisabeth Bjork, a director at Rocket Pharmaceuticals Inc, has acquired an additional 10,000 shares of the company, bringing her total ownership to 40,000 shares. This purchase is part of a broader trend of insider buying at Rocket Pharmaceuticals, although there have been more insider sales than buys over the past year. The stock was trading at $3.41 on the day of the purchase, with a market cap of $358.241 million. Insider buying can be a positive signal for investors, but should be considered in conjunction with other factors such as GF Value and analyst projections.

Elisabeth Bjork, a director at Rocket Pharmaceuticals Inc. (NASDAQ: RCKT), has recently acquired an additional 10,000 shares of the company, increasing her total ownership to 40,000 shares. This purchase was made on August 27, 2025, at a price of $3.41 per share, totaling $34,100 [2].

The insider buying at Rocket Pharmaceuticals is part of a broader trend, although it is notable that there have been more insider sales than buys over the past year. This latest purchase comes amidst significant market activity for the company, with shares trading at $3.41 on the day of the transaction, and a market cap of $358.241 million [2].

The FDA's lifting of the clinical hold on the pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease has been a key driver of Rocket Pharmaceuticals' stock performance. The stock jumped 15.8% to $3.37 in the pre-market trading session following this announcement [1]. This positive development has led to increased investor interest and insider buying.

While insider buying can be a positive signal for investors, it should be considered in conjunction with other factors such as GF Value and analyst projections. Several institutional investors have increased their positions in Rocket Pharmaceuticals, including Mather Group LLC, Parallel Advisors LLC, and Brooklyn Investment Group, among others [3]. Despite these positive trends, some analysts maintain a "Hold" rating on the stock, with a consensus target price of $15.81, while UBS Group has set a price objective of $16.00 [3].

Rocket Pharmaceuticals' stock has shown strong volume and movement, with a 50-day moving average of $15.49 and a 200-day moving average of $13.93. The company's revenue for the quarter was up 4.5% on a year-over-year basis, with earnings per share of $0.04, beating the consensus estimate by $0.01 [3]. However, the company's negative net margin and high debt-to-equity ratio of 2.36 warrant caution.

In summary, the insider buying at Rocket Pharmaceuticals is a positive sign, but investors should consider the broader market trends and analyst projections when evaluating the company's stock. The FDA's lifting of the clinical hold on RP-A501 is a significant development, but the company's financial performance and debt levels should also be closely monitored.

References:
[1] https://www.inkl.com/news/why-rocket-pharmaceuticals-shares-are-trading-higher-by-over-15-here-are-20-stocks-moving-premarket
[2] https://www.tradingview.com/news/tradingview:8dcc22136c220:0-rocket-pharmaceuticals-director-elisabeth-bjork-buys-10-000-shares/
[3] https://www.marketbeat.com/instant-alerts/filing-emg-holdings-lp-sells-20748-shares-of-rocket-companies-inc-rkt-2025-08-25/